Emerging therapeutic targets for patients with advanced prostate cancer

Prostate cancer represents the leading cause of cancer in men, with 164,690 new cases expected to be diagnosed in the United States, in 2018 [1]. Significant progress has been made in the past several years in the treatment of castration-resistant prostate cancer (CRPC), with the approval of effective agents with unique mechanisms of action, including docetaxel, enzalutamide, abiraterone acetate, cabazitaxel, sipuleucel T, radium 223 dichloride, and apalutamide [2 –10]. Nonetheless, clinically significant prostate cancer remains associated with substantial mortality, as it currently represents the second most common cause of cancer death in men (9% of all cancer deaths), due to the development of acquired resistance to sequential lines of treatment and the associated disease progression [1,11,12].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: New Drugs Source Type: research